GRAIL (GRAL) Stock Price, News & Analysis

Company Overview

GRAIL, Inc. is a healthcare company focused on developing blood-based tests for the early detection of cancer. Its technology uses genomic and epigenomic signals, including patterns of DNA methylation, to identify signals associated with multiple cancer types from a single blood sample.

The company’s primary product is Galleri, a prescription blood test designed to screen for signals of more than 50 types of cancer, including cancers that currently lack recommended screening methods. Galleri is intended to complement, not replace, guideline-recommended cancer screenings, and a positive result requires follow-up diagnostic testing to determine whether cancer is present and where it may be located.

GRAIL was founded in 2016 as a subsidiary of Illumina and became an independent publicly traded company following its separation from Illumina in 2021. The company is headquartered in Menlo Park, California, and primarily serves the U.S. market. GRAIL has also participated in research and commercial initiatives involving health systems, employers, and international partners to evaluate the use of multi-cancer early detection testing.

Key Stats

• Today's Range: $74.27 to $77.93
• 50-Day Range: $63.40 to $82.54
• 52-Week Range: $36.98 to $118.84
• Volume: 1.51 million shs
• Average Volume: 617,014 shs
• Market Capitalization: $3.39 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $71.11
• Consensus Rating: Hold

GRAIL Stock Analysis - MarketRank™

GRAIL scored higher than 13% of companies evaluated by MarketBeat, and ranked 863rd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Hold

Consensus Rating

GRAIL has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on no strong buy ratings, 5 buy ratings, 5 hold ratings, and 1 sell rating.

Downside Risk

GRAIL has a consensus price target of $71.11, representing about 6.3% downside from its current price of $75.89.

Amount of Analyst Coverage

GRAIL has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for GRAIL are expected to decrease in the coming year, from ($10.41) to ($10.70) per share.

Price to Book Value per Share Ratio

GRAIL has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.41% of the float of GRAIL has been sold short.

Short Interest Ratio / Days to Cover

GRAIL has a short interest ratio ("days to cover") of 12.28, which indicates bearish sentiment.

Change versus previous month

Short interest in GRAIL has recently increased by 4.38%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GRAIL does not currently pay a dividend.

Dividend Growth

GRAIL does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.78

News Sentiment

GRAIL has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for GRAIL this week, compared to 9 articles on an average week.

Search Interest

Only 1 people have searched for GRAL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added GRAIL to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, GRAIL insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,096,679.00 in company stock.

Percentage Held by Insiders

1.83% of the stock of GRAIL is held by insiders.

Percentage Held by Institutions

GRAIL has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/15/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GRAL
• Previous Symbol: NASDAQ:GRAL
• CIK: 1699031
• Web: grail.com
• Phone: (833) 694-2553
• Fax: N/A
• Employees: 910
• Year Founded: 2016

Price Target and Rating

• Average Price Target for GRAIL: $71.11
• High Price Target: $105.00
• Low Price Target: $56.00
• Potential Upside/Downside: -6.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.36
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($9.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$408.35 million
• Net Margins: -236.95%
• Pretax Margin: -320.38%
• Return on Equity: -15.88%
• Return on Assets: -14.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.95
• Quick Ratio: 10.95

Sales & Book Value

• Annual Sales: $147.17 million
• Price / Sales: 23.03
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $66.13 per share
• Price / Book: 1.15

Miscellaneous

• Outstanding Shares: 44,670,000
• Free Float: 43,849,000
• Market Cap: $3.39 billion
• Optionable: Optionable
• Beta: 3.25